Recent Company Profiles and Reports

Atrium Research (March 17, 2025)
BIOREM AGM 2025
BIOREM Investor Series - Growth Strategy

2025 TSX Venture 50 Company

BIOREM was selected by the TMX Group as one of the 2025 TSX Venture 50 upcoming companies on the TSX Venture Exchange. The selection means that BIOREM is one of the top performing companies when ranked by one-year share price appreciation, market capitalization increase, and Canadian consolidated trading value.

Press Releases

Subscribe to Press Releases

Panels and Interviews

Investor Resources Contact Form

Financial Statements

YearQuarterTypeDocument
2025Quarter 1Statement2025-Q1
2025Quarter 1MD&A2025-Q1-MD&A
2024Quarter 4Statement2024-Q4
2024Quarter 4MD&A2024-Q4-MD&A
2024Quarter 3Statement 2024-Q3
2024Quarter 3 MD&A2024-Q3-MD&A
2024Quarter 2Statement 2024-Q2
2024Quarter 2MD&A2024-Q2-MD&A
2024Quarter 1Statement2024-Q1
2024Quarter 1MD&A2024-Q1-MD&A
2023Quarter 4/YearlyStatement2023-Q4
2023Quarter 4/YearlyMD&A2023-Q4-MD&A

2023		Quarter 3Statement2023-Q3

2023		Quarter 3MD&A2023-Q3-MD&A
2023Quarter 2Statement2023-Q2
2023Quarter 2MD&A2023-Q2-MD&A

2023		Quarter 1Statement2023-Q1

2023		Quarter 1MD&A2023-Q1-MD&A
2022Quarter 4/YearlyStatement2022-Q4
2022Quarter 4/YearlyMD&A2022-Q4-MD&A
2022Quarter 3Statement2022-Q3
2022Quarter 3MD&A2022-Q3-MD&A
2022Quarter 2Statement2022-Q2
2022Quarter 2MD&A2022-Q2-MD&A
2022Quarter 1Statement2022-Q1
2022Quarter 1MD&A2022-Q1-MD&A
2021Quarter 4/YearlyStatement2021-Q4
2021Quarter 4/YearlyMD&A2021-Q4-MD&A
2021Quarter 3Statement2021-Q3
2021Quarter 3MD&A2021-Q3-MD&A
2021Quarter 2Statement2021-Q2
2021Quarter 2MD&A2021-Q2-MD&A
2021Quarter 1Statement2021-Q1
2021Quarter 1MD&A2021-Q1-MD&A
2020Quarter 4/YearlyStatement2020-Q4
2020Quarter 4/YearlyMD&A2020-Q4-MD&A
2020Quarter 3Statement2020-Q3
2020Quarter 3MD&A2020-Q3-MD&A
2020Quarter 2Statement2020-Q2
2020Quarter 2MD&A2020-Q2-MD&A
2020Quarter 1Statement2020-Q1
2020Quarter 1MD&A2020-Q1-MD&A
2019Quarter 4/YearlyStatement2019-Q4
2019Quarter 4/YearlyMD&A2019-Q4-MD&A
2019Quarter 3Statement2019-Q3
2019Quarter 3MD&A2019-Q3-MD&A
2019Quarter 2Statement2019-Q2
2019Quarter 2MD&A2019-Q2-MD&A
2019Quarter 1Statement2019-Q1
2019Quarter 1MD&A2019-Q1-MD&A
2018Quarter 4/YearlyStatement2018-Q4
2018Quarter 4/YearlyMD&A2018-Q4-MD&A
2018Quarter 3Statement2018-Q3
2018Quarter 3MD&A2018-Q3-MD&A
2018Quarter 2Statement2018-Q2
2018Quarter 2MD&A2018-Q2-MD&A
2018Quarter 1Statement2018-Q1
2018Quarter 1MD&A2018-Q1-MD&A
2017Quarter 4/YearlyStatement2017-Q4
2017Quarter 4/YearlyMD&A2017-Q4-MD&A
2017Quarter 3Statement2017-Q3
2017Quarter 3MD&A2017-Q3-MD&A
2017Quarter 2Statement2017-Q1
2017Quarter 2MD&A2017-Q2-MD&A
2017Quarter 1Statement2017-Q1
2017Quarter 1MD&A2017-Q1-MD&A
2016Quarter 4/YearlyStatement2016-Q4
2016Quarter 4/YearlyMD&A2016-Q4-MD&A
2015Quarter 4/YearlyStatement2015-Q4
2015Quarter 4/YearlyMD&A2015-Q4-MD&A
2014Quarter 4/YearlyStatement2014-Q4
2014Quarter 4/YearlyMD&A2014-Q4-MD&A
2013Quarter 4/YearlyStatement2013-Q4
2013Quarter 4/YearlyMD&A2013-Q4-MD&A
2012Quarter 4/YearlyStatement2012-Q4
2012Quarter 4/YearlyMD&A2012-Q4-MD&A
2011Quarter 4/YearlyStatement2011-Q4
2011Quarter 4/YearlyMD&A2011-Q4-MD&A
2010Quarter 4/YearlyStatement2010-Q4
2010Quarter 4/YearlyMD&A2010-Q4-MD&A
2009Quarter 4/YearlyStatement2009-Q4
2009Quarter 4/YearlyMD&A2009-Q4-MD&A
2008Quarter 4/YearlyStatement2008-Q4
2008Quarter 4/YearlyMD&A2008-Q4-MD&A
2007Quarter 4/YearlyStatement2007-Q4
2006Quarter 4/YearlyMD&A2007-Q4-MD&A